BioXcel Therapeutics

BTAI

Market cap $49.2M

2.25 USD

+0.17

8.17%

At close Updated Nov 28, 4:00 PM EST

Pre-market

After hours

2.23

-0.02

0.89%

1 day

8.17%

5 days

28.57%

1 month

3.21%

3 months

-45.12%

6 months

78.57%

Year to date

-64.11%

1 year

-65.6%

5 years

-99.68%

10 years

-98.73%

About: BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Employees: 37

Healthcare Biotechnology